Universitätsklinikum Carl Gustav Carus Dresden

Characteristics and Outcomes of Adolescents (15–18 Years) with Chronic Myelogenous Leukemia (CML) in Chronic Phase: The Experience of the International Registry of Childhood CML † (2026) Millot F, Froment M, Durocher L, Metzler M, De Moerloose B, Brandalise SR, Borisevich M, et al. Journal article Ausgründung als Verwertungsstrategie von Verbundprojekten (2026) Li MM, Langes B, Sonnabend D, Stoll S, Grauer T, Bartelheimer C, Baturov S, et al. Other publication type, Whitepaper How personality functioning shapes symptom development during and after treatment: A random intercept cross lagged panel analysis (2026) Fuchshuber J, Kessler H, Kehyayan A, Pape M, Hofmann T, Rose M, Imbierowicz K, et al. Journal article Translating ctDNA into cutaneous melanoma care: An international expert survey (2026) Geidel G, Fekade N, Raabe K, Smit DJ, Adam L, Heidrich I, Rünger A, et al. Journal article Delphi consensus on gene therapy of spinal muscular atrophy with onasemnogene abeparvovec in Germany, Austria and Switzerland-part I-systematic literature review and existing evidence (2026) Weiß C, Vill K, Baumann M, Bernert G, Blaschek A, Eisenkölbl A, Flotats-Bastardas M, et al. Journal article Brain morphology in Anorexia Nervosa and its subtypes: A multi-cohort study of individual participant data (2026) Bernardoni F, Arold D, Schoppik L, Bahnsen K, Ge R, Moreau C, Bang L, et al. Journal article S2k-Leitlinie Berufliche Hautmittel: Hautschutz, Hautpflege und Hautreinigung (2026) Gina M, Fartasch M, Bauer A, Drexler H, Elsner P, Geier J, John SM, et al. Journal article Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR database (2026) Käs F, Elhai M, Becker MO, Dobrota R, Mihai C, Sauer G, Tofani L, et al. Journal article HISTAI: a valuable dataset with a valuable lesson (2026) Hewitt KJ, Reitsam NG, Foersch S, Erber R, Zeng Q, Kather JN Journal article Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial (2026) Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article